NMN vs NR (Nicotinamide Riboside): NAD+ Bioavailability & Human Longevity Trials
Head-to-head clinical evaluation of Nicotinamide Mononucleotide (NMN) vs Nicotinamide Riboside (NR) examining Slc12a8 vs NRK1 cellular uptake pathways, whole-blood NAD+ elevation, and functional biomarkers in human clinical trials.
Key Clinical Takeaways & Systematic Review Summary
Head-to-head clinical evaluation of Nicotinamide Mononucleotide (NMN) vs Nicotinamide Riboside (NR) examining Slc12a8 vs NRK1 cellular uptake pathways, whole-blood NAD+ elevation, and functional biomarkers in human clinical trials.
- Evidence Classification: Rigorously graded under standardized Cochrane & GRADE systematic review protocols.
- Literature Benchmark Dosage: NMN: 600–1,000mg/day | NR: 500–1,000mg/day.
- Pharmacokinetic Timing: Morning administration on an empty stomach; co-administration with Resveratrol enhances SIRT1 activation..
- Active Primary PubMed Reference: PMID 36481744 (GeroScience).
Participate in Paid Clinical Research Studies ($750–$2,200 Stipends)
Accredited medical research centers are actively enrolling qualified participants for metabolic health, incretin therapy, and longevity studies. All physician evaluations, lab panels, and investigational compounds are provided at zero cost.
Check Clinical Trial Match Eligibility →Interactive Clinical Calculators & Drug Interaction Checkers
Calculate individualized body-weight dosages, check contraindications against prescription medications, and analyze 24-hour synergy schedules using our free interactive tool suite: